Macmillan is pushing the Welsh government to ensure all those diagnosed with cancer are routinely given financial advice.
Macmillan Cancer Support has highlighted rising fuel poverty among cancer sufferers and called for Government support.
Cancer Research UK's commercial arm, Cancer Research Technology, (CRT), and the European Investment Fund (EIF) have created a £50m investment fund bridging a funding gap between cancer drug discovery and early development.
AXA PPP healthcare is supporting the UK's largest women only fundraising event, Cancer Research UK's Race for Life 2012.
Scottish Provident has announced that it paid out £90 million to critical illness policyholders during 2011, with 91% of all critical illness claims paid.
Group Risk Development (Grid) has released the first ever full set of collated claims figures from the group risk industry.
The government's controversial welfare reforms have received Royal Ascent and so been adopted into law.
Two more cancer drugs have been provisionally banned for NHS after it was decided they were too expensive for the potential results.
Axa PPP has extended its cancer coverage to include the clinically effective prostate cancer drug rejected for the NHS because it is too expensive.
The government looks set to force through its controversial welfare reforms without giving the House of Lords a chance to readdress the amendments it made.